Sex Differences Underlying Preexisting Cardiovascular Disease and Cardiovascular Injury in COVID-19

Overview

Journal J Mol Cell Cardiol

Specialty Cardiology & Vascular Diseases

Date 2020 Aug 25

PMID 32835666

Citations 21

Authors

Lejla Medzikovic

Christine M Cunningham

Min Li

Marjan Amjedi

Jason Hong

Gregoire Ruffenach

Mansoureh Eghbali

Affiliations

Soon will be listed here.

Abstract

The novel 2019 coronavirus disease (COVID-19), resulting from severe acute respiratory syndrome coronarvirus-2 (SARS-CoV-2) infection, typically leads to respiratory failure in severe cases; however, cardiovascular injury is reported to contribute to a substantial proportion of COVID-19 deaths. Preexisting cardiovascular disease (CVD) is among the most common risk factors for hospitalization and death in COVID-19 patients, and the pathogenic mechanisms of COVID-19 disease progression itself may promote the development of cardiovascular injury, increasing risk of in-hospital death. Sex differences in COVID-19 are becoming more apparent as mounting data indicate that males seem to be disproportionately at risk of severe COVID-19 outcome due to preexisting CVD and COVID-19-related cardiovascular injury. In this review, we will provide a basic science perspective on current clinical observations in this rapidly evolving field and discuss the interplay sex differences, preexisting CVD and COVID-19-related cardiac injury.

Citing Articles

The impact of sex/gender-specific funding and editorial policies on biomedical research outcomes: a cross-national analysis (2000-2021).

Kim H, Park J, Ahn S, Lee H Sci Rep. 2024; 14(1):26599.

PMID: 39496696 PMC: 11535369. DOI: 10.1038/s41598-024-77018-0.

Cardiac Magnetic Resonance Imaging of COVID-19-Associated Cardiac Sequelae: A Systematic Review.

Boparai M, Musheyev B, Khan U, Koduru T, Hinson J, Skopicki H Rev Cardiovasc Med. 2024; 23(12):389.

PMID: 39076661 PMC: 11270474. DOI: 10.31083/j.rcm2312389.

[Study analysis evaluating the management and epidemiological aspects of the COVID-19 pandemic in Senegal one year on].

Bousso A, Sonko I, Lakhe A, Ly A, Ba P, Dieng A Pan Afr Med J. 2023; 46:5.

PMID: 37928220 PMC: 10620444. DOI: 10.11604/pamj.2023.46.5.30693.

Sex differences in cardiovascular complications and mortality in hospital patients with covid-19: registry based observational study.

Hockham C, Linschoten M, Asselbergs F, Ghossein C, Woodward M, Peters S BMJ Med. 2023; 2(1):e000245.

PMID: 37067859 PMC: 10083523. DOI: 10.1136/bmjmed-2022-000245.

Cardiac abnormalities in Long COVID 1-year post-SARS-CoV-2 infection.

Roca-Fernandez A, Wamil M, Telford A, Carapella V, Borlotti A, Monteiro D Open Heart. 2023; 10(1).

PMID: 36822818 PMC: 9950586. DOI: 10.1136/openhrt-2022-002241.

References

Monteil V, Kwon H, Prado P, Hagelkruys A, Wimmer R, Stahl M . Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. Cell. 2020; 181(4):905-913.e7. PMC: 7181998. DOI: 10.1016/j.cell.2020.04.004. View

Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F . Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. Eur Heart J. 2020; 41(22):2070-2079. PMC: 7239100. DOI: 10.1093/eurheartj/ehaa408. View

Shen C, Ge J . Epidemic of Cardiovascular Disease in China: Current Perspective and Prospects for the Future. Circulation. 2018; 138(4):342-344. DOI: 10.1161/CIRCULATIONAHA.118.033484. View

Tukiainen T, Villani A, Yen A, Rivas M, Marshall J, Satija R . Landscape of X chromosome inactivation across human tissues. Nature. 2017; 550(7675):244-248. PMC: 5685192. DOI: 10.1038/nature24265. View

Lala A, Johnson K, Januzzi J, Russak A, Paranjpe I, Richter F . Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection. J Am Coll Cardiol. 2020; 76(5):533-546. PMC: 7279721. DOI: 10.1016/j.jacc.2020.06.007. View

Iorga A, Cunningham C, Moazeni S, Ruffenach G, Umar S, Eghbali M . The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017; 8(1):33. PMC: 5655818. DOI: 10.1186/s13293-017-0152-8. View

Burrell L, Risvanis J, Kubota E, Dean R, Macdonald P, Lu S . Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005; 26(4):369-75. DOI: 10.1093/eurheartj/ehi114. View

Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry B . Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis (Berl). 2020; 7(2):91-96. DOI: 10.1515/dx-2020-0046. View

Toraih E, Elshazli R, Hussein M, Elgaml A, Amin M, El-Mowafy M . Association of cardiac biomarkers and comorbidities with increased mortality, severity, and cardiac injury in COVID-19 patients: A meta-regression and decision tree analysis. J Med Virol. 2020; 92(11):2473-2488. PMC: 7307124. DOI: 10.1002/jmv.26166. View

10.

Yoshida H, Rosano G, Shimizu M, Mochizuki S, Yoshimura M . Gender differences in the effects of angiotensin receptor blockers on cardiovascular disease. Curr Pharm Des. 2011; 17(11):1090-4. DOI: 10.2174/138161211795656909. View

11.

Gopinathannair R, Merchant F, Lakkireddy D, Etheridge S, Feigofsky S, Han J . COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies. J Interv Card Electrophysiol. 2020; 59(2):329-336. PMC: 7268965. DOI: 10.1007/s10840-020-00789-9. View

12.

Gupta N, Davis C, Nelson J, Young J, Alkayed N . Soluble epoxide hydrolase: sex differences and role in endothelial cell survival. Arterioscler Thromb Vasc Biol. 2012; 32(8):1936-42. PMC: 3417749. DOI: 10.1161/ATVBAHA.112.251520. View

13.

Akhmerov A, Marban E . COVID-19 and the Heart. Circ Res. 2020; 126(10):1443-1455. DOI: 10.1161/CIRCRESAHA.120.317055. View

14.

Chen L, Li X, Chen M, Feng Y, Xiong C . The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020; 116(6):1097-1100. PMC: 7184507. DOI: 10.1093/cvr/cvaa078. View

15.

Reynolds H, Adhikari S, Pulgarin C, Troxel A, Iturrate E, Johnson S . Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020; 382(25):2441-2448. PMC: 7206932. DOI: 10.1056/NEJMoa2008975. View

16.

Lippi G, Lavie C, Sanchis-Gomar F . Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020; 63(3):390-391. PMC: 7127395. DOI: 10.1016/j.pcad.2020.03.001. View

17.

Epelman S, Tang W, Chen S, Van Lente F, Francis G, Sen S . Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol. 2008; 52(9):750-4. PMC: 2856943. DOI: 10.1016/j.jacc.2008.02.088. View

18.

Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C . QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm. 2020; 17(9):1425-1433. PMC: 7214283. DOI: 10.1016/j.hrthm.2020.05.014. View

19.

Lazzerini P, Acampa M, Laghi-Pasini F, Bertolozzi I, Finizola F, Vanni F . Cardiac Arrest Risk During Acute Infections: Systemic Inflammation Directly Prolongs QTc Interval via Cytokine-Mediated Effects on Potassium Channel Expression. Circ Arrhythm Electrophysiol. 2020; 13(8):e008627. DOI: 10.1161/CIRCEP.120.008627. View

20.

Fraga-Silva R, Sorg B, Wankhede M, DeDeugd C, Jun J, Baker M . ACE2 activation promotes antithrombotic activity. Mol Med. 2010; 16(5-6):210-5. PMC: 2811560. DOI: 10.2119/molmed.2009.00160. View